Samyang Biopharm said its in-house NanoReady messenger RNA (mRNA) cancer-vaccine delivery system carried about 20 times more mRNA per particle than conventional lipid nanoparticles (LNP) and showed no systemic toxicity after repeat dosing in a preclinical study. The findings were published on the 20th in the Journal of Controlled Release and selected as a cover article. Built on the company’s SENS gene-delivery platform, NanoReady combines proprietary lipids with biodegradable polymers and selectively delivers mRNA to spleen dendritic cells that initiate immune responses. In non-human primate testing, cancer-antigen mRNA delivered through NanoReady induced a T-cell response. The vehicle can be manufactured and stored without mRNA before being mixed with patient-specific cancer-antigen information, potentially shortening production of personalized cancer vaccines. Samyang Biopharm plans to develop its own mRNA cancer vaccine and expand SENS applications through global licensing and joint development. The company’s results come as MSD conducts a Phase 3 trial combining the personalized mRNA cancer vaccine intismeran autogene with Keytruda Qlex in non-small cell lung cancer, while GI Innovation conducts a Phase 2 trial of GI-102, an immuno-oncology candidate based on Keytruda and interleukin-2. These developments highlight demand for delivery systems and immune boosters that can strengthen responses to patient-specific tumor mutations.